Tumour necrosis factor alpha suppression by MDMA is mediated by peripheral heteromeric nicotinic receptors

Immunopharmacology and Immunotoxicology

Volumn 32, Issue 2, 2010, Pages 265-271

  Camarasa, Jorge ^a   Ros, Clara ^a   Pubill, David ^a   Escubedo, Elena ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Ecstasy; MDMA; Mice; Nicotinic receptors; Rat; TNF

Indexed keywords

CITRATE SODIUM; DIHYDRO BETA ERYTHROIDINE; EDETIC ACID; HEXAMETHONIUM; LIPOPOLYSACCHARIDE; METHYLLYCACONITINE; N METHYL DEXTRO ASPARTIC ACID; NICOTINIC RECEPTOR BETA2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; LONG TERM EXPOSURE; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NICOTINIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; SPECIES SPECIFICITY; STREET DRUGS; TUMOR NECROSIS FACTOR-ALPHA;

MUS; RATTUS; RODENTIA;

EID: 77952178250     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923970903295104     Document Type: Article

References (31)

1. Green AR, Mechan AO, Elliott JM, OShea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 2003;55:463-508.
2. Chipana C, Camarasa J, Pubill D, Escubedo E. Protection against MDMA-induced dopaminergic neurotoxicity in mice by methyllycaconitine: involvement of nicotinic receptors. Neuropharmacology 2006;51:885-895.
3. Schwartz RH, Miller NS. MDMA (ecstasy) and the rave: a review. Pediatrics 1997;100:705-708.
4. Hegadoren KM, Baker GB, Bourin M. 3,4-Methylenedioxy analogues of amphetamine: Defining the risks to humans. Neurosci Biobehav Rev 1999;23:539-553.
5. Series H, Boeles S, Dorkins E, Peveler R. Psychiatric complications of Ecstasy use. J Psychopharmacol 1994;8:60-61.
6. Connor TJ. Methylenedioxymethamphetamine (MDMA, ecstasy): a stressor on the immune system. Immunology 2004;111: 357-367.
7. Connor TJ, Kelly JP, McGee M, Leonard BE. Methylenedioxymethamphetamine (MDMA; Ecstasy) suppresses IL-1β and TNF-α secretion following an in vivo lipopolysaccharide challenge. Life Sci 2000;67:1601-1612.
8. Connor TJ, Dennedy MC, Harkin A, Kelly JP. Methylenedioxymethamphetamine- induced suppression of interleukin-1β and tumour necrosis factor-α is not mediated by serotonin. Eur J Pharmacol 2001;418:147-152.
9. Pacifici R, Zuccaro P, Hernandez C, Pichini S, Di Carlo S, Farre M, et al. Acute effects of 3,4-methylene-dioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther 2001;296:207-215.
10. Ulloa L. The vagus nerve and the nicotinic anti-inflammatory pathway. Nat Rev Drug Discov 2005;4:673-684.
11. Kawashima K, Yoshikawa K, Fujii YX, Moriwaki Y, Misawa H. Expression and function of genes encoding cholinergic components in murine immune cells. Life Sci 2007;80:2314-2319.
12. García-Ratés S, Camarasa J, Escubedo E, Pubill D. Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their up-regulation. Toxicol Appl Pharmacol 2007;223:195-205.
13. Chipana C, Camarasa J, Pubill D, Escubedo E. Memantine prevents MDMA-induced neurotoxicity. Neurotoxicology 2008; 29: 179-183.
14. Klingler W, Heffron JJ, Jurkat-Rott K, OSullivan G, Alt A, Schlesinger F, et al. 3,4-Methylenedioxymethamphetamine (ecstasy) activates skeletal muscle nicotinic acetylcholine receptors. J Pharmacol Exp Ther 2005;314:1267-1273.
15. Chipana C, Torres I, Camarasa J, Pubill D, Escubedo E. Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents. Neuropharmacology 2008;54:1254-1263.
16. Chipana C, García-Ratés S, Camarasa J, Pubill D, Escubedo E. Different oxidative profile and nicotinic receptor interaction of amphetamine and 3,4-methylenedioxy-methamphetamine. Neurochem Int. 2008;52:401-410.
17. Wooters TE, Bardo MT. Nicotinic receptors differentially modulate the induction and expression of behavioural sensitization to methylphenidate in rats. Psychopharmacology 2009;204:551-562.
18. Neumann S, Razen M, Habermehl P, Meyer CU, Zepp F, Kirkpatrick CJ, et al. The non-neuronal cholinergic system in peripheral blood cells: effects of nicotinic and muscarinic receptor antagonists on phagocytosis, respiratory burst and migration. Life Sci 2007;80:2361-2364.
19. Pubill D, Chipana C, Camins A, Pallas M, Camarasa J, Escubedo E. Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol Appl Pharmacol 2005; 204:57-68.
20. Escubedo E, Chipana C, Pérez-Sánchez M, Camarasa J, Pubill D. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: Involvement of alpha 7 nicotinic receptors. J Pharmacol Exp Ther 2005;315:658-667.
21. Panagis G, Kastellakis A, Spyraki C, Nomikos G. Effects of methyllycaconitine (MLA), an alpha-7 nicotinic receptor antagonist, on nicotine- and cocaine-induced potentiation of brain stimulation reward. Psychopharmacology 2000;149:388-396.
22. Solinas M, Scherma M, Fattore L, Stroik J, Wertheim C, Tanda G, et al. Nicotinic alpha-7 receptors as a new target for treatment of cannabis abuse. J Neurosci 2007;27:5615-5620.
23. Camarasa J, Marimón JM, Rodrigo T, Escubedo E, Pubill D. Memantine prevents the cognitive impairment induced by 3,4- methylenedioxymethamphetamine in rats. Eur J Pharmacol 2008;589:132-139.
24. Connor TJ, Harkin A, Kelly JP. Methylenedioxymethamphetamine suppresses production of proinflammatory cytokine tumor necrosis factor-α independent of a β-adrenoceptor-mediated increase in interleukin-10. J. Pharmacol Exp Ther 2005; 312:134-143.
25. Connor TJ, Kelly JP. Fenfluramine-induced immunosuppression: an in vivo analysis. Eur J Pharmacol 2002;455:175-185.
26. Flora G, Lee YW, Nath A, Maragos W, Hennig B, Toborek M. Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation. Neuromol Med 2002;2:71-85.
27. Nakajima A, Yamada K, Nagai T, Uchiyama T, Miyamoto Y, Mamiya T, He J, Nitta A, Mizuno M, Tran MH, Seto A, et al. Role of tumour necrosis factor-α in methamphetamine-induced dependence and neurotoxicity. J Neurosci 2004;24: 2212-2225.
28. De Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 2007;151:915-929.
29. Buisson B, Bertrand D. Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol Sci 2002; 23:130-136.
30. Fenster CP, Whitworth TL, Sheffield EB, Quick MW, Lester RA. Upregulation of surface alpha4beta2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine. J Neurosci 1999;19:4804-4814.
31. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S Li, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421: 384-388.